COMP <GO>
ADCT vs AKBA // OPERATING MARGIN
ADC Therapeutics SA (NYSE) VS. Akebia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ADCT 3
— AKBA 5
▲ OPERATING MARGIN LEADER: AKBA
LAST: $1.54 (+0.65%) • MKT CAP: $196.6M
operating-margins
-60.00%
LAST: $0.71 (+0.27%) • MKT CAP: $196.3M
operating-margins
9.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADCT VS. AKBA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADCT | AKBA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.90% | 83.30% | +9.60 | ADCT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 85.00% | -120.00 | AKBA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 4.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | 9.90% | -69.90 | AKBA | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -2.20% | -57.80 | AKBA | /net-margins <GO> |
| Revenue Growth (YoY) | 14.90% | 47.50% | -32.60 | AKBA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | AKBA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 45.2 | +9.10 | ADCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $196.6M | $196.3M | $306.2K | ADCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADCT REV | AKBA REV | ADCT GROSS % | AKBA GROSS % | ADCT FCF | AKBA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $81.4M | $236.2M | 92.9% | 83.3% | -$141.4M | $67.7M |
| FY 2024 | $70.8M | $160.2M | 91.6% | 60.6% | -$124.7M | -$40.7M |
| FY 2023 | $69.1M | $194.6M | — | — | -$118.7M | -$23.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADCT // BETA —
AKBA // BETA —